Tradewinds LLC. Increases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Tradewinds LLC. grew its stake in Pfizer Inc. (NYSE:PFE) by 21.8% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,423 shares of the biopharmaceutical company’s stock after acquiring an additional 2,046 shares during the quarter. Tradewinds LLC.’s holdings in Pfizer were worth $289,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of PFE. Meridian Investment Counsel Inc. boosted its holdings in Pfizer by 7.2% during the 1st quarter. Meridian Investment Counsel Inc. now owns 69,874 shares of the biopharmaceutical company’s stock valued at $1,771,000 after acquiring an additional 4,717 shares during the period. McGlone Suttner Wealth Management Inc. lifted its stake in Pfizer by 63.6% during the first quarter. McGlone Suttner Wealth Management Inc. now owns 20,023 shares of the biopharmaceutical company’s stock worth $507,000 after purchasing an additional 7,784 shares during the last quarter. Sierra Ocean LLC lifted its stake in Pfizer by 117.3% during the first quarter. Sierra Ocean LLC now owns 2,757 shares of the biopharmaceutical company’s stock worth $70,000 after purchasing an additional 1,488 shares during the last quarter. Lee Danner & Bass Inc. increased its position in Pfizer by 3.2% during the first quarter. Lee Danner & Bass Inc. now owns 115,269 shares of the biopharmaceutical company’s stock worth $2,921,000 after buying an additional 3,524 shares during the period. Finally, Olistico Wealth LLC increased its position in Pfizer by 1,522.0% during the first quarter. Olistico Wealth LLC now owns 8,110 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 7,610 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Up 0.5%

Pfizer stock opened at $25.45 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The firm has a market capitalization of $144.66 billion, a price-to-earnings ratio of 18.44, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The stock’s fifty day moving average is $23.72 and its two-hundred day moving average is $24.82.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. Pfizer’s revenue was down 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.82 earnings per share. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.76%. Pfizer’s dividend payout ratio is currently 124.64%.

Analysts Set New Price Targets

Several research firms have commented on PFE. BMO Capital Markets cut their price target on Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. Wolfe Research boosted their target price on Pfizer from $22.00 to $23.00 and gave the company an “underperform” rating in a report on Wednesday, April 30th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Leerink Partners dropped their target price on Pfizer from $28.00 to $26.00 and set a “market perform” rating on the stock in a report on Wednesday, April 30th. Finally, UBS Group boosted their target price on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $28.55.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.